BioDelivery Sciences pain drug fails late: stage study

(Reuters) - BioDelivery Sciences International Inc said its pain drug failed to meet the main goal of a late-stage study, sending the drugmaker's shares down nearly 30 percent premarket.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1xsyvmG